Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Transgenomic Licenses Exclusive Rights to Multiplexed Ice Cold-PCRTM Technology

Published: Wednesday, May 28, 2014
Last Updated: Thursday, May 29, 2014
Bookmark and Share
Multiplexed Version of Revolutionary Technology Enables Efficient Detection of Multiple Cancer Mutations in a Single Liquid Assay

Transgenomic, Inc. announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology.
 
The new license is exclusive to Transgenomic and expands the current relationship with Dana-Farber. It covers all fields and applications of the multiplexed technology, which makes possible the simultaneous detection of multiple DNA mutations from a single liquid sample, such as blood or urine.
 
Paul Kinnon, President and Chief Executive Officer of Transgenomic commented, “We believe MX ICE COLD-PCR is a critical enabling technology that represents a major leap forward in individualized cancer therapy. For the first time, it will allow comprehensive and affordable tumor genomic profiling without the need for tumor biopsies, a prerequisite if ongoing monitoring and optimization of cancer therapy is to become an everyday reality.”
 
Mr. Kinnon continued, “Multiplexing makes our ICE COLD-PCR technology far more efficient and allows us to assemble targeted panels of relevant mutations that can be simultaneously analyzed from a single sample. This should greatly increase its availability for routine use in cancer therapy, as well as for our biopharmaceutical customers who plan to use MX ICE COLD-PCR to develop new cancer treatments and companion diagnostics.”
 
ICE COLD-PCR selectively focuses on only the mutated DNA in tumors that is useful for cancer diagnosis, monitoring and treatment. It detects mutated DNA at very high sensitivity—initial validation studies show it is 100-400 fold more sensitive than conventional approaches. Uniquely, ICE COLD-PCR also enables identification of all tumor mutations – both those already known to cancer researchers as well as new mutations not detected before.
 
Importantly, the ultra-high sensitivity of ICE COLD-PCR allows DNA testing to be done using easily accessible samples, such as blood, plasma and urine, eliminating the need for tumor biopsies, which are invasive, painful and expensive. By enabling the use of these “liquid biopsies”, ICE COLD-PCR makes it possible to conduct repeated assessments of a cancer patient’s disease status both initially and as treatment proceeds, providing valuable information to help guide treatment decisions.
 
ICE COLD-PCR can also analyze DNA from fine needle aspirates, core-biopsies, or directly from tumors, and it can be used with standard Sanger sequencing, next generation sequencing, digital PCR and other technologies, as research in Dr. Mike Makrigiorgos’ lab at Dana-Farber Cancer Institute has shown.
 
Transgenomic’s current version of the ICE COLD-PCR technology is also exclusively licensed from Dana-Farber.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Transgenomic Awarded NIH Grant
STTR grant supports addition of greater multiplexing capabilities to ICE COLD-PCR, an advanced technology that enables use of tissue or liquid biopsy samples and provides up to 500-fold increase in mutation detection on any sequencing platform.
Monday, January 04, 2016
Transgenomic Licenses Liquid Biopsy Technology to University of Melbourne
Commercial agreement for Australia allows University of Melbourne to use Transgenomic’s multiplexed ICE COLD-PCR™ product for cancer diagnostics and biomarker identification.
Friday, September 18, 2015
Transgenomic, Raptor to Collaborate
Transgenomic to provide genetic profiling for Raptor's clinical trial evaluating drug for the treatment of Leigh Syndrome and other mitochondrial disorders.
Friday, April 04, 2014
Transgenomic Acquires ScoliScore™ AIS Prognostic Test from Axial Biotech
Commercially established, highly accurate test reduces dangerous radiation exposure in adolescents diagnosed with Scoliosis.
Wednesday, August 29, 2012
Transgenomic and The Medical College Of Wisconsin Announce Collaboration
Transgenomic will offer next-generation genetic testing services performed at the MCW Clinical Sequencing Program.
Monday, July 30, 2012
Transgenomic Announces $3 Million Convertible Note Financing
The company announced it has entered into a Convertible Promissory Note Purchase Agreement in the aggregate amount of $3.0 million with entities associated with Third Security, LLC.
Monday, January 09, 2012
Transgenomic, Inc. To Purchase Clinical Data, Inc.'s Diagnostic Business
Transgenomic, Inc. announced today the signing of a definitive agreement for Transgenomic to acquire the diagnostic business of Clinical Data, Inc.
Tuesday, November 30, 2010
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Accessing Metabolic Information with Mass Spec
Scientists at the Helmholtz Zentrum München have developed a new mass spectrometry imaging method which, for the first time, makes it possible to analyze hundreds of metabolites in fixed tissue samples.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!